Nobel Prize winner died of pancreatic cancer

Share This Post

Dr. Thomas A. Steitz died on October 9, 2018 at the age of 78, and died of pancreatic cancer. Steitz is the co-winner of the 2009 Nobel Prize in Chemistry.

Steitz’s research on the ribosome has had a profound impact, making the atomic structure of the ribosome more clear. The ribosome is the main force that leads the genes encoded into DNA to be “translated” into proteins. Steitz’s work is directly related to the biological mechanism that causes pancreatic cancer. As we all know, pancreatic cancer and other cancer types are caused by genetic changes. When errors or mutations occur in the genetic code, these errors can pass through the ribosome and cause the production of abnormal proteins. The activity of these abnormal proteins causes healthy cells to become cancer cells and spread in the body. Researchers are doing further research to design new targeted therapies to directly block the activity of abnormal proteins in pancreatic cancer cells.

The Pancreatic Cancer Action Network (PanCAN) is deeply grateful to Steitz for his contributions to understanding cell and molecular biology, and expresses his condolences to his family, friends and colleagues.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

LungVax lung cancer vaccine
Lung cancer

LungVax: Lung cancer vaccine

LungVax is an innovative lung cancer vaccine designed to stimulate the immune system to target and destroy cancer cells. It is engineered to enhance the body’s natural defense mechanisms against tumor growth, offering a novel approach to lung cancer treatment. LungVax aims to prevent recurrence in high-risk patients and improve survival rates, marking a promising development in immunotherapy for one of the deadliest forms of cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy